FDA-approved cancer drug doses may be too high, researchers say

A Kaiser Health News investigation reveals patients and researchers believe many cancer drug dosages, including immunotherapies like Keytruda and Opdivo, are excessive. Reducing these amounts could save billions and lessen severe side effects. This isn't about whether the drugs work, but about how much of them we actually need to get the benefit without the brutal cost to the body.